ESC Professional Premium Access

What defines risk in acute coronary syndromes

Event: ESC Congress 2022
Topic: Epidemiology, Prognosis, Outcome
Session type: Abstract Sessions
Date: 29 August 2022
Time: 11:30 - 12:30

Congress Session

Become an ESC Professional member to access this resource

Become a member

Already a member? Sign in

6 presentations in this session

Bleeding risk in patients hospitalized for non-ST-segment elevation acute coronary syndromes in Switzerland: performance of the CRUSADE score

Speaker: Doctor F. Wenzl (Zurich, CH)
Thumbnail

Clinical risk scores versus simple integrated clinical judgment in patients with suspected acute coronary syndromes

Speaker: Doctor J. Boeddinghaus (Edinburgh, GB)
Thumbnail

Metabolic associated fatty liver disease increases risk of adverse events after acute coronary syndrome.

Speaker: Doctor N. Chew (Singapore, SG)
Thumbnail

Sex inequities in the performance of the GRACE 2.0 score in non-ST-segment elevation acute coronary syndromes: a multinational observational study in contemporary cohorts from four European countries

Speaker: Doctor F. Wenzl (Zurich, CH)
Thumbnail

Long-term non-cardiovascular morbidity risk remains elevated following myocardial infarction: a nationwide cohort study

Speaker: Doctor D. Christensen (Copenhagen, DK)
Thumbnail

Association of ischemic and bleeding events with mortality in patients with a recent acute myocardial infarction

Speaker: Ms M. Simonsson (Stockholm, SE)
Thumbnail

6 speakers from this session

Doctor Florian Alexander Wenzl

University of Zurich, Zurich (Switzerland)
0 follower

Doctor Jasper Boeddinghaus

Royal Infirmary of Edinburgh at Little France, Edinburgh (United Kingdom of Great Britain & Northern Ireland)
2 presentations
0 follower

Doctor Nicholas Chew

National University Health System, Singapore (Singapore)
0 follower

Doctor Florian Alexander Wenzl

University of Zurich, Zurich (Switzerland)
0 follower

Doctor Daniel Molager Christensen

Danish Heart Foundation, Copenhagen (Denmark)
1 follower

Ms Moa Simonsson

Karolinska Institute, Stockholm (Sweden)
1 presentation
0 follower

This platform is supported by

logo Novo Nordisk